Related Experiment Videos
Aspirin in the treatment and prevention of cardiovascular disease
1Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Insights
Aspirin use reduces risks of vascular events like heart attack and stroke in secondary prevention. Primary prevention data in men shows reduced first heart attack risk, with ongoing trials clarifying benefits for women.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Aspirin irreversibly inhibits cyclooxygenase (COX) in platelets.
- This inhibition has potential clinical benefits in reducing occlusive vascular events.
Purpose of the Study:
- To review the clinical benefits of aspirin in secondary and primary prevention of vascular events.
- To highlight the current evidence gaps in primary prevention, particularly for women.
Main Methods:
- Review of randomized trial data on aspirin's efficacy in vascular event prevention.
- Analysis of benefits in secondary prevention across various occlusive vascular conditions.
- Examination of primary prevention data, noting limitations and ongoing research.
Main Results:
- Aspirin therapy is associated with reduced risks of subsequent myocardial infarction (MI), stroke, and vascular deaths in secondary prevention.
- In acute MI, aspirin demonstrates clear benefits for subsequent events and vascular mortality.
- Primary prevention data in men shows a reduced risk of a first MI, but effects on stroke and total mortality are inconclusive.
Conclusions:
- Aspirin is beneficial in secondary prevention of vascular events and in acute MI.
- Further research, including trials in women, is needed to fully establish the benefits and risks of aspirin in primary prevention.
Abstract:
Aspirin irreversibly inhibits cyclooxygenase in platelets for their entire lifespan, raising the possibility of clinical benefits by decreasing risks of occlusive vascular events. In secondary prevention among patients with a wide range of prior occlusive vascular events, including myocardial infarction (MI), stroke, transient ischemic attacks (TIAs), as well as unstable and chronic stable angina, aspirin therapy is associated with a reduction in risks of subsequent MI, stroke, and vascular deaths. In acute MI, aspirin also confers clear benefits on subsequent MI, stroke, and vascular deaths. In primary prevention, the available randomized trial data, which to date are limited to men, indicate a clear reduction in risk of a first MI; the current data are inconclusive concerning aspirin's effect on stroke and total vascular mortality. A currently ongoing trial among 40,000 apparently healthy women will provide reliable data concerning the balance of benefits and risks of aspirin in primary prevention.